What’s Next for HIV Vaccines:
From Design to Efficacy Testing

Satellite Session at IAS 2015




The rapidly evolving field of HIV prevention research includes several promising strategies to prevent or treat HIV with a vaccine. The Enterprise and stakeholders organized a 2-hour, interactive session at IAS 2015 on July 19 to explore the latest in HIV vaccine design, development and testing.

The session addressed questions such as:

  • What are the most promising, cross-platform approaches in development for preventive and therapeutic vaccines?
  • Where are we in efforts to build on the success of the RV144 trial?
  • What is the field learning from studies on novel immunogen design, unique vector platforms, mosaic antigen inserts and prime-boost vaccine regimens?
  • What is the role of emerging strategies to administer broadly neutralizing antibodies by passive immunization?
  • How do innovative efficacy trial designs optimize the evaluation of HIV vaccine candidates?

Speakers and Panelists

  • Nina Russell, Bill & Melinda Gates Foundation
  • Mary Marovich, National Institute of Allergy and Infectious Diseases
  • Nelson Michael, US Military HIV Research Program
  • Dan Barouch, Beth Israel Deaconess Medical Center
  • Allan deCamp, HIV Vaccine Trials Network
  • Frank Tomaka, Janssen Pharmaceuticals

Organized by the Stakeholders of the Enterprise

  • Bill & Melinda Gates Foundation
  • HIV Vaccine Trials Network
  • International AIDS Vaccine Initiative
  • Institut National de la Santé et de la Recherche Médicale
  • US Military HIV Research Program
  • National Institute of Allergy and Infectious Diseases

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account